Pursuant to Regulation 30 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015 ('SEBI LODR Regulations'), as amended from time to time, this is to inform that ....
Price
▲ positive · ▼ negative · ● neutral filings · teal = economic event · numbered = multiple that day (click to pick). Times IST.
Awaiting price reaction for this filing.
Covidh Technologies Limited has signed a non-binding Letter of Intent (LOI) on February 23, 2026, to acquire 100% equity shareholding of iSERA Biological Private Limited. Once the deal closes, iSERA will become a wholly owned subsidiary of Covidh Technologies. The transaction is still subject to signing of definitive agreements, satisfactory due diligence, and receipt of regulatory, statutory, and shareholder approvals. iSERA appears to operate in the biological/biotech space, signalling Covidh's potential entry or expansion into that sector. The LOI itself is non-binding except for standard clauses around confidentiality, exclusivity, governing law, and costs.
This is an early-stage announcement and the deal is far from finalised, so any near-term stock reaction may be muted or speculative. Shareholders should track upcoming updates on definitive agreements, due diligence findings, and required approvals before drawing firm conclusions.